Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | TERT | O14746 | 2/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22529434 | 0.90 | L3MBTL1 (0.67) | CYP3A4L3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL10323936 | 0.87 | NPC1 (0.62) | CYP3A4L3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL15107476 | 0.86 | L3MBTL1 (0.74) | CYP3A4L3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL1878130 | 0.84 | CYP3A4 (0.67) | CYP3A4L3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL1520594 | 0.84 | CYP3A4 (0.67) | CYP3A4L3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL10323935 | 0.84 | TERT (0.54) | CYP3A4L3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL23857903 | 0.83 | CYP3A4 (0.65) | CYP3A4L3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL7820017 | 0.83 | CYP3A4 (0.65) | CYP3A4L3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL3674141 | 0.83 | CYP3A4 (0.75) | CYP3A4L3MBTL1ALDH1A1EPHX1EPHX2 | |
| SCHEMBL5675525 | 0.81 | MEN1 (0.52) | CYP3A4L3MBTL1MAPTALDH1A1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| EP-2475653-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| WO-2011029537-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-17 | — | — | WO | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-7601748-B2 | Anti-androgenic N-[ omega -[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines; treatment of prostate cancer, benign prostate hyperplasia, androgenetic alopecia, hirsutism or acne | BAYER SCHERING PHARMA AG (DE) | 2009-10-13 | — | — | US | disclosed |
| WO-2009081197-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| EP-1622894-B1 | ANTITUMORAL ANTIANDROGENIC PYRROLIDINES | BAYER SCHERING PHARMA AG (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008044033-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| US-20070021481-A1 | Anti-androgenic pyrrolidines with tumor-inhibiting action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | US | disclosed |
| US-7138421-B2 | Anti-androgenic pyrrolidines with tumor-inhibiting action | SCHRING AKTIENGESELLSCHAFT (DE) | 2006-11-21 | — | — | US | disclosed |
| EP-1622894-A1 | ANTITUMORAL ANTIADROGENIC PYRROLIDINES | Schering Aktiengesellschaft (DE) | 2006-02-08 | — | — | EP | disclosed |
| US-20050159468-A1 | Anti-androgenic pyrrolidines with tumor-inhibiting action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-21 | — | — | US | disclosed |
| US-6861432-B2 | Piperazine derivatives that destabilize androgen receptors | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| WO-2004099188-A1 | ANTITUMORAL ANTIADROGENIC PYRROLIDINES | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-18 | — | — | WO | disclosed |
| US-20040009969-A1 | Piperazine derivatives that destabilize androgen receptors | SCHERING AG (DE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003043983-A1 | PIPERAZINE DERIVATIVES DESTABILISING ANDROGEN RECEPTORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021481-A1 | Anti-androgenic pyrrolidines with tumor-inhibiting action | NR5A1, AR, CYP17A1 | CYP3A4 978/4885L3MBTL1 4878/4885MAPT 4842/4885 |
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | TPMT, BPHL, VHL | CYP3A4 172/4885L3MBTL1 3199/4885MAPT 3235/4885 |
| US-20050159468-A1 | Anti-androgenic pyrrolidines with tumor-inhibiting action | NR5A1, AR, CYP17A1 | CYP3A4 978/4885L3MBTL1 4878/4885MAPT 4842/4885 |
| US-20040009969-A1 | Piperazine derivatives that destabilize androgen receptors | AR, FSHR, GNRHR | CYP3A4 1870/4885L3MBTL1 4567/4885MAPT 4808/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | CYP3A4 316/4885L3MBTL1 4752/4885MAPT 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.